The Syneos Health Podcast
The Syneos Health Podcast Series dissects some of the most complex issues biopharma leaders are facing today. Our clinical and commercial experts provide time-tested solutions, as well as perspectives on the news of the day. Hosted by Jeff Stewart, a long-time industry consultant who has advised biopharma leaders on licensing, mergers and acquisitions, pricing and market access, commercialization and go-to-market strategies, each episode explores the challenges and considerations involved with bringing biopharmaceuticals to the market.
Podcasting since 2017 • 145 episodes
The Syneos Health Podcast
Latest Episodes
Decoding Gen AI’s Potential to Drive More Effective Clinical Trials
AI is seemingly everywhere now in our lives, including healthcare and drug discovery and development. AI certainly has the potential to enable major advances than development of more effective and safe medical products. And in fact, GenAI has a...
August 21, 2024
•
31:32
Connecting the Global Dots on Carbon Footprint in Biopharma
The World Economic Forum projects that by 2050, climate change could cause 14 million additional deaths and $12 trillion in global healthcare costs. And this will exacerbate global health inequities with our most vulnerable populations, includi...
July 09, 2024
•
27:16
Can AI Help Get the Right Patients Into Alzheimer's Clinical Trials?
Alzheimer's disease is a challenging and devastating diagnosis that affects memory and cognitive skills, with no known way to predict, track, treat, or cure it effectively. In 2024, around 90 million people over the age of 65 will be living wit...
May 31, 2024
•
31:58
Unpacking the Role of Adjuvant Therapies in Breast Cancer
Breast cancer is the most common type of cancer among women worldwide, and it can be treated with different modalities, such as surgery, chemotherapy, radiation, hormone therapy and targeted therapy. However, even after the primary treatment, s...
May 23, 2024
•
28:11
Site and Study Execution for Ophthalmology Trials
This is an exciting time in the development of new medicines to treat both rare and age-related eye diseases. But what is it like in the trenches to develop and deliver clinical trials that evaluate both the safety and efficacy of these potenti...
May 08, 2024
•
18:34